Adtran and Iridium strengthen PNT resilience in Europe and Asia-Pacific with Satellite Time and Location technology
24.6.2024 15:00:00 EEST | Business Wire | Press release
Adtran, in partnership with Iridium Communications Inc. (NASDAQ: IRDM), today announced the European and Asia-Pacific launch of its synchronization solutions featuring Iridium® Satellite Time and Location (STL) technology, a significant step in countering growing threats to Global Navigation Satellite Systems (GNSS). Adtran’s OSA 5405-S PTP compact grandmaster clock with STL capabilities and its OSA 5400 STL module are now available to timing network operators in Western Europe, major countries in Eastern Europe, Turkey, and parts of Asia-Pacific, including the majority of Southeast Asia, Japan and South Korea. The solutions enhance the resilience and reliability of critical infrastructure, such as 5G networks, defense systems and many more. Leveraging low-Earth orbit (LEO) satellites to deliver precise and secure positioning, navigation and timing (PNT) services, the devices ensure continuous synchronization even in environments where GNSS is compromised. As a certified Iridium partner, Adtran offers the technology through two distinct purchasing options: an annual service license for optimal flexibility or bundled with equipment for long-term financial planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240624939927/en/
Adtran’s synchronization solution featuring Iridium® STL services will bring new levels of PNT security to Europe and Asia-Pacific. (Photo: Business Wire)
“The weakness of GNSS signals is increasingly being exploited to create serious problems. As Europe, APAC and the rest of the world have become more dependent on PNT data, attacks on GNSS have only escalated, creating an urgent need to pivot away from the exclusive use of these satellites,” said Michael O’Connor, executive vice president of PNT at Iridium. “By integrating our STL service into Adtran Oscilloquartz devices and making it available across much of Europe and key areas of APAC, we’re providing network operators with valuable new options. They can choose to use our solution as a primary source of timing data in indoor environments, or they can leverage our secure, high-strength LEO signals as a backup source of PNT information when GNSS is unavailable. This offers the strongest ever safeguard against the threats that compromise so many aspects of our daily lives.”
Iridium® STL services harness the power of LEO satellites to transmit encrypted signals that are 1,000 times stronger than those of GNSS, significantly reducing vulnerability to disruptions and manipulation. The technology excels in challenging environments like urban canyons and indoor areas and can penetrate deep into buildings without the need for rooftop antennas. STL services are now a key feature of Adtran’s Oscilloquartz product lineup. The versatile OSA 5405-S PTP grandmaster clock supports STL time services and multi-constellation GNSS, as well as various other timing sources, all within a zero-trust architecture that leverages multiple diverse timing sources for enhanced resilience. Additionally, the OSA 5400 STL module extends these advanced STL/GNSS receiver capabilities to third-party equipment requiring timing, enabling precise, robust synchronization for a wide range of applications.
“We partnered with Iridium to bring the benefits of its STL services to critical timing infrastructure around the world because we share a common goal. We’re committed to making PNT networks as resilient and secure as possible. STL is a powerful solution for fortifying zero-trust architecture and ensuring reliable PNT even when GPS signals fail, making it ideal for both indoor and challenging outdoor locations. By empowering operators of mission-critical networks to access reliable timing in the most demanding environments, we’re also eliminating the need to install outdoor antennas and core through concrete, significantly reducing expenses,” commented Gil Biran, GM of Oscilloquartz, Adtran. “We’re excited to bring these advantages to so many more customers across Europe and APAC. Today’s announcement marks a significant advancement for the network operators and people of these regions, whose daily lives increasingly depend on robust PNT.”
Adtran is making STL services readily available in ways that perfectly align with the evolving needs of modern network infrastructures, offering two purchasing models designed to maximize operational flexibility and support financial planning. The ‘opex model’ provides an annual service license, which is ideal for operators that need adaptable yearly budgeting. Conversely, the ‘capex model’ bundles STL services with essential equipment for 3, 5 or 10 years, facilitating cost amortization similar to traditional GNSS systems. These options make the benefits of LEO satellite signals – whether as a robust primary timing source or a highly reliable backup to GNSS – accessible to sectors where reliable and secure PNT is paramount, including 5G, data centers, smart grids and defense.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240624939927/en/
Contacts
For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com
For investors
Rhonda Lambert
+1 256 963 7450
investor@adtran.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom